Pfizer Revenue 2010-2022 | PFE

Pfizer annual/quarterly revenue history and growth rate from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Pfizer revenue for the quarter ending December 31, 2022 was $24.290B, a 1.9% increase year-over-year.
  • Pfizer revenue for the twelve months ending December 31, 2022 was $100.331B, a 23.43% increase year-over-year.
  • Pfizer annual revenue for 2022 was $100.33B, a 23.43% increase from 2021.
  • Pfizer annual revenue for 2021 was $81.288B, a 95.16% increase from 2020.
  • Pfizer annual revenue for 2020 was $41.651B, a 1.82% increase from 2019.
Pfizer Annual Revenue
(Millions of US $)
2022 $100,330
2021 $81,288
2020 $41,651
2019 $40,905
2018 $40,825
2017 $52,546
2016 $52,824
2015 $48,851
2014 $49,605
2013 $51,584
2012 $54,657
2011 $61,035
2010 $65,165
2009 $49,269
Pfizer Quarterly Revenue
(Millions of US $)
2022-12-31 $24,290
2022-09-30 $22,638
2022-06-30 $27,742
2022-03-31 $25,661
2021-12-31 $23,838
2021-09-30 $24,035
2021-06-30 $18,899
2021-03-31 $14,516
2020-12-31 $11,427
2020-09-30 $10,277
2020-06-30 $9,864
2020-03-31 $10,083
2019-12-31 $1,843
2019-09-30 $12,680
2019-06-30 $13,264
2019-03-31 $13,118
2018-12-31 $1,155
2018-09-30 $13,298
2018-06-30 $13,466
2018-03-31 $12,906
2017-12-31 $13,703
2017-09-30 $13,168
2017-06-30 $12,896
2017-03-31 $12,779
2016-12-31 $13,627
2016-09-30 $13,045
2016-06-30 $13,147
2016-03-31 $13,005
2015-12-31 $14,047
2015-09-30 $12,087
2015-06-30 $11,853
2015-03-31 $10,864
2014-12-31 $13,118
2014-09-30 $12,361
2014-06-30 $12,773
2014-03-31 $11,353
2013-12-31 $13,558
2013-09-30 $12,643
2013-06-30 $12,973
2013-03-31 $12,410
2012-12-31 $12,851
2012-09-30 $12,953
2012-06-30 $13,968
2012-03-31 $14,885
2011-12-31 $11,439
2011-09-30 $16,609
2011-06-30 $16,485
2011-03-31 $16,502
2010-12-31 $15,462
2010-09-30 $15,995
2010-06-30 $17,132
2010-03-31 $16,576
2009-12-31 $15,797
2009-09-30 $11,621
2009-06-30 $10,984
2009-03-31 $10,867
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $247.323B $100.330B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $430.370B 16.20
Eli Lilly (LLY) United States $322.186B 42.71
Novo Nordisk (NVO) Denmark $309.552B 39.42
Merck (MRK) United States $260.994B 13.76
AbbVie (ABBV) United States $256.783B 10.65
Novartis AG (NVS) Switzerland $189.952B 14.05